The roles of TPL in hematological malignancies

References

• Kupchan SM, et al. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc. 1972 Oct 4;94(20):7194–7195.
   PubMed Web of Science ®Google Scholar
• Datta R, Oki E, Endo K, et al. XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem. 2000;275(41):31733–8.
   PubMed Web of Science ®Google Scholar
• EfferthT LP, KonkimallaVS KB. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med. 2007;13(8):353–361.
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu J, Zhang B, et al. Therapeutic potential of triptolide as an anti-inflammatory agent in dextran sulfate sodium-induced murine experimental colitis. Front Immunol. 2020 Nov 9;11:592084.
   PubMed Web of Science ®Google Scholar
• Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett. 2008;270(2):337–341.
   PubMed Web of Science ®Google Scholar
• Philips P, Borja-Cacho D, Dudeja V, et al. Triptolide a potential therapeutic candidate for pancreatic cancer. J Am Coll Surg. 2007;205:S94.
   Web of Science ®Google Scholar
• Zhou GX, Ding XL, Huang JF, et al. Apoptosis of human pancreatic cancer cells induced by Triptolide. World J Gastroenterol. 2008;14:1504–1509.
   PubMed Web of Science ®Google Scholar
• Kang DW, Lee JY, Oh DH, et al. Triptolide-induced suppression of phospholipase D expression inhibits proliferation of MDA-MB-231 breast cancer cells. Exp Mol Med. 2009;41:678–685.
   PubMed Web of Science ®Google Scholar
• Westfall SD, Nilsson EE, Skinner MK. Role of triptolide as an adjunct chemother-apy for ovarian cancer. Chemotherapy. 2008;54:67–76.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Kornblau SM, Tsao T, et al. Caspase- independent cell death inAML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003;102:4179–4186.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Milella M, Tsao T, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003;17:2081–2089.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak DH, Schober WD, et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood. 2006 Jul 15;108(2):630–637.
   PubMed Web of Science ®Google Scholar
• Yuan-Fei Shi Y, Liu L, He L-L, et al. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020 Jul 22;11(7):555.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhao H, Ye J, et al. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo. Mol Carcinog. 2020 Sep;59(9):1076–1087.
   PubMed Web of Science ®Google Scholar
• Carter BZ, Mak DH, Schober WD, et al. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 2008;111:3742–3750.
   PubMed Web of Science ®Google Scholar
• Li M, Zhang X, Zhou W-J, et al. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance. Acta Pharmacol Sin. 2013;34:1545–1553.
   PubMed Web of Science ®Google Scholar
• Zhou M, Gu L, Abshire T, et al. Incidence and prognostic significance of MDM2 on coprotein over expression in relapsed childhood acute lymphoblastic leukemia. Leukemia. 2000;14:61–67.
   PubMed Web of Science ®Google Scholar
• Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell. 1998;95:5–8.
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, et al. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993;7:1126–1132.
   PubMed Web of Science ®Google Scholar
• Coleman ML, Sahai EA, Yeo M, et al. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol. 2001;3:339–345.
   PubMed Web of Science ®Google Scholar
• Sebbagh M, Renvoize C, Hamelin J, et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol. 2001;3:346–352.
   PubMed Web of Science ®Google Scholar
• Parent N, Sane AT, Droin N, et al. Procaspase-2S inhibits procaspase-3 processing and activation, preventing ROCK-1-mediated apoptotic blebbing and body formation in human B lymphoma Namalwa cells. Apoptosis. 2005;10:313–322.
   PubMed Web of Science ®Google Scholar
• Chang J, Xie M, Shah VR, et al. Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis. Proc Natl Acad Sci USA. 2006;103:14495–14500.
   PubMed Web of Science ®Google Scholar
• Liu L, Li G, Li Q, et al. Triptolide induces apoptosis in human leukemia cells through caspase-3-mediated ROCK1 activation and MLC phosphorylation. Cell Death Dis. 2013 Dec 5;4(12):e941.
   PubMedGoogle Scholar
• Park S-W, Kim YI. Triptolide induces apoptosis of PMA-treated THP-1 cells through activation of caspases, inhibition of NF-κB and activation of MAPKs. Int J Oncol. 2013 Oct;43(4):1169–1175.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lu Z, Jin Y, et al. Triptolide inhibits Jak2 transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1. Cancer Lett. 2010 May 28;291(2):246–255.
   PubMed Web of Science ®Google Scholar
• Meng H-t, Zhu L, Ni W-m, et al. Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*. Acta Pharmacol Sin. 2011 Apr;32(4):503–511.
   PubMed Web of Science ®Google Scholar
• Lou YJ, Jin J. Triptolide Down-regulates Bcr-abl Expression and Induces Apoptosis in Chronic Myelogenous Leukemia Cells. Leuk Lymphoma. 2004 Feb;45(2):373–376.
   PubMed Web of Science ®Google Scholar
• Shi X, Jin Y, Cheng C, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 2009 Mar 1;15(5):1686–1697.
   PubMed Web of Science ®Google Scholar
• Zhou G-S, Hu Z, Fang H-T, et al. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res. 2011 Feb;35(2):214–218.
   PubMed Web of Science ®Google Scholar
• Wen L, Chen Y, Zeng L-l, et al. Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B. Acta Pharmacol Sin. 2012 Jan;33(1):109–119.
   PubMed Web of Science ®Google Scholar
• Zhao F, Chen Y, Li R, et al. Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology. 2010 Jan 12;267(1-3):70–79.
   PubMed Web of Science ®Google Scholar
• Li H, Hui L, Xu W, et al. Triptolide modulates the sensitivity of K562/A02 cells to adriamycin by regulating miR-21 expression. Pharm Biol. 2012 Oct;50(10):1233–1240.
   PubMed Web of Science ®Google Scholar
• White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009 Sep 1;15(17):5308–5316.
   PubMed Web of Science ®Google Scholar
• White EJ, Martin V, Liu JL, et al. Autophagy regulation in cancer development and therapy. Am J Cancer Res. 2011;1(3):362–372.
   PubMed Web of Science ®Google Scholar
• Cho DH, Jo YK, Hwang JJ, et al. Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett. 2009 Feb 8;274(1):95–100.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhao L, Liu L, et al. Beclin 1 cleavage by caspase-3 inactivates autophagy and promotes apoptosis. Protein Cell. 2010 May;1(5):468–477.
   PubMed Web of Science ®Google Scholar
• Kang R, Zeh HJ, Lotze MT, et al. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011 Apr;18(4):571–580.
   PubMed Web of Science ®Google Scholar
• Li H, Wang P, Sun Q, et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res. 2011 May 15;71(10):3625–3634.
   PubMed Web of Science ®Google Scholar
• Chan S-F, Chen Y-Y, Lin J-J, et al. Triptolide induced cell death through apoptosis and autophagy in murine leukemia WEHI-3 cells in vitro and promoting immune responses in WEHI-3 generated leukemia mice in vivo. Environ Toxicol. 2017 Feb;32(2):550–568.
   PubMed Web of Science ®Google Scholar
• Escherich G, Zimmermann M, Janka-Schaub G. Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07–03. Pediatr Blood Cancer. 2013 Feb;60(2):254–257.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Thompson JE, Wang ES, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer. 2011 Apr 15;117(8):1583–1594.
   PubMed Web of Science ®Google Scholar
• Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;127:1551–1558.
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N. Engl J Med. 2009;361:1249–1259.
   PubMed Web of Science ®Google Scholar
• Murphy T, Yee KWL. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. Expert Opin Pharmacother. 2017 Nov;18(16):1765–1780.
   PubMed Web of Science ®Google Scholar
• Ji JH, Min S, Chae S, et al. De novo phosphorylation of H2AX by WSTF regulates transcription-coupled homologous recombination repair. Nucleic Acids Res. 2019;47:6299–6314.
   PubMed Web of Science ®Google Scholar
• Chen F, Liu Y, Wang S, et al. Triptolide, a Chinese herbal extract, enhances drug sensitivity of resistant myeloid leukemia cell lines through downregulation of HIF-1a and Nrf2. Pharmacogenomics. 2013 Aug;14(11):1305–1317.
   PubMed Web of Science ®Google Scholar
• Matsunaga T, Imataki O, Torii E, et al. Elevated HIF-1a expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res. 2012 Jun;36(6):e122–e124.
   PubMed Web of Science ®Google Scholar
• Mak DH, Schober WD, Chen W, et al. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34t primitive progenitor cells. Mol Cancer Ther. 2009;8:2509–2516.
   PubMed Web of Science ®Google Scholar
• Wilczynski J, Duechler M, Czyz M. Targeting NF-aB and HIF-1 pathways for the treatment of cancer: part I. Arch. Immunol. Ther. Exp. (Warsz.). 2011;59(4):289–299.
   PubMedGoogle Scholar
• Wilczynski J, Duechler M, Czyz M. Targeting NF-kB and HIF-1 pathways for the treatment of cancer: part II. Arch. Immunol. Ther. Exp. (Warsz.). 2011;59(4):301–307.
   PubMedGoogle Scholar
• Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, et al. HIF-1a modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009 Aug;9(9):1084–1101.
   PubMed Web of Science ®Google Scholar
• Tang X, Wang H, Fan L, et al. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic Biol Med. 2011;50:1599–1609.
   PubMed Web of Science ®Google Scholar
• Zhao H, Shi P, Deng M, et al. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. Oncotarget. 2016 Dec 20;7(51):85515–85528.
   PubMedGoogle Scholar
• Blagosklonny MV, Robey R, Bates S, et al. Pre-treatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest. 2000;105:533–539.
   PubMed Web of Science ®Google Scholar
• Amico D, Barbui AM, Erba E, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood. 2003;101:4589–4597.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sui JZ, Zhu LH, et al. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022;30(5):1474–1481.
   PubMedGoogle Scholar
• Srinivasarao M, Low PS. Ligand-Targeted Drug Delivery. Chem Rev. 2017 Oct 11;117(19):12133–12164.
   PubMed Web of Science ®Google Scholar
• Piao X, Zhou J, Xue L. Triptolide decreases rheumatoid arthritis fibroblast-like synoviocyte proliferation, invasion, inflammation and presents a therapeutic effect in collagen-induced arthritis rats via inactivating lncRNA RP11-83J16.1 mediated URI1 and β-catenin signaling. Int Immunopharmacol. 2021;99:108010.
   PubMed Web of Science ®Google Scholar
• Wu H, et al. Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma. Exp Ther Med. 2019;17(5):3291–3298.
   PubMed Web of Science ®Google Scholar
• Giri B, Gupta VK, Yaffe B, et al. Pre-clinical evaluation of minnelide as a therapy for acute myeloid leukemia. J Transl Med. 2019;17(163.
   Google Scholar
• Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014 Mar;4(3):362–375.
   PubMed Web of Science ®Google Scholar
• Burchert A. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica. 2021 Mar 1;106(3):664–670.
   PubMed Web of Science ®Google Scholar
• Röllig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16(16):1691–1699.
   PubMed Web of Science ®Google Scholar
• Chen Y-B, Li S, Lane AA, et al. Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2014;20(12):2042–2048.
   PubMed Web of Science ®Google Scholar
• Wang X, Ma L-M, Wang T, et al. [Effect of Low-Dose Triptolide and Sorafenib Alone and Their Combination on AML Cell Line MV411 and the Pathway of STAT5]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1088–1093.
   PubMedGoogle Scholar
• Lauten M, Beger C, Gerdes K, et al. Expression of heat-shock protein 90 in glucocorticoid-sensitive and -resistant childhood acute lymphoblastic leukaemia. Leukaemia. 2003;17:1551–1556.
   PubMed Web of Science ®Google Scholar
• Hacıhanefioglu A, Gonullu E, Mehtap O, et al. Effect of heat shock protein-90 (HSP90) and vascular endothelial growth factor (VEGF) on survival in acute lymphoblastic leukemia: an immunohistochemical study. Med Oncol. 2011;28:846–851.
   PubMed Web of Science ®Google Scholar
• Tong WG, Estrov Z, Wang Y, et al. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011;29:1206–1212.
   PubMed Web of Science ®Google Scholar
• Lundgren K, Zhang H, Brekken J, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009;8:921–929.
   PubMed Web of Science ®Google Scholar
• Yu W, Denu RA, Krautkramer KA, et al. Loss of SIRT3 Provides Growth Advantage for B Cell Malignancies. J Biol Chem. 2016 Feb 12;291(7):3268–3279.
   PubMed Web of Science ®Google Scholar
• Kong T, et al. Triptolide induces mitochondria-mediated apoptosis of Burkitt, s lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression. Toxicol Appl Pharmacol. 2018;342:1–13.
   PubMed Web of Science ®Google Scholar
• Li Z, et al. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents. J Med Chem. 2009 Aug 27;52(16):5115–5123.
   PubMed Web of Science ®Google Scholar
• Xu H, et al. Design, synthesis and anticancer activity evaluation of novel C14 heterocycle substituted epi-triptolide. Eur J Med Chem. 2014 Feb 12;73:46–55.
   PubMed Web of Science ®Google Scholar
• Noel P, Von Hoff DD, Saluja AK, et al. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019 May;40(5):327–341.
   PubMed Web of Science ®Google Scholar
• Fidler JM, et al. PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2003 Sep;2(9):855–862.
   PubMed Web of Science ®Google Scholar
• Li M, et al. NF-kB signaling inhibition and anticancer activities of LLDT-246 on human colorectal cancer HCT-116 cells in vitro. Biomed Pharmacother. 2014 Jun;68(5):527–535.
   PubMed Web of Science ®Google Scholar
• Xu H, et al. LLDT-288, a novel triptolide analogue exhibits potent antitumor activity in vitro and in vivo. Biomed Pharmacother. 2017 Sep;93:1004–1009.
   PubMed Web of Science ®Google Scholar
• Tang W, Zuo J. Immunosuppressant discovery from Tripterygium wilfordii Hook f: the novel triptolide analog (5R)-5- hydroxytriptolide (LLDT-8). Acta Pharmacol Sin. 2012 Sep;33(9):1112–1118.
   PubMed Web of Science ®Google Scholar
• Fu YF, et al. (5R)-5-Hydroxytriptolide (LLDT-8), a novel triptolide derivative, prevents experimental autoimmune encephalomyelitis via inhibiting T cell activation. J Neuroimmunol. 2006 Jun;175(1-2):142–151.
   PubMed Web of Science ®Google Scholar
• Liu Y, et al. Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors. Cell Death Dis. 2013 Dec 5;4(12):e948.
   PubMedGoogle Scholar
• Greeno E, Borazanci E, Gockerman J, et al. Abstract CT207: Phase I dose escalation and pharmokinetic study of 14-O-phosphonooxymethyltriptolide. Philadelphia: AACR; 2015.
   Google Scholar
• Carter BZ, et al. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 2012 Mar;26(3):443–450.
   PubMed Web of Science ®Google Scholar
• Reno TA, et al. The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer. BMC Cancer. 2016 Jul 11;16:439.
   PubMed Web of Science ®Google Scholar
• Fidler JM, et al. Preclinical antileukemic activity, toxi-cology, toxicokinetics and formulation development of triptolide derivative MRx102. Cancer Chemother Pharmacol. 2014 May;73(5):961–974.
   PubMed Web of Science ®Google Scholar
• Wen SQ, Ma LM, Lu YJ, et al. Triptolide inhibits proliferation and induces apoptosis of imatinib resistant K562/G01 cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Oct;21(5):1148–1152.
   PubMedGoogle Scholar
• Ma Y, Li Y, Huang M, et al. Triptolide inhibits T-cell acute lymphoblastic leukaemia by affecting aberrant epigenetic events in the Wnt signalling pathway. J Chemother. 2022 Jun 6: 1–10.
   PubMed Web of Science ®Google Scholar
• Nakazato T, Sagawa M, Kizaki M. Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1. Int J Oncol. 2014;44(4):1131–1138.
   PubMed Web of Science ®Google Scholar
• Zhao F, Chen Y, Zeng L-l, et al. Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cells. Acta Pharmacol Sin. 2010;31(6):733–740.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Park B. Triptolide blocks the STAT3 signaling pathway through induction of protein tyrosine phosphatase SHP-1 in multiple myeloma cells. Int J Mol Med. 2017;40(5):1566–1572.
   PubMed Web of Science ®Google Scholar
• Wen L, et al. Triptolide induces cell apoptosis by targeting H3K4me3 and downstream effector proteins in KM3 multiple myeloma cells. Curr Pharm Biotechnol. 2015;17(2):147–160.
   PubMed Web of Science ®Google Scholar
• Yinjun L, et al. Triptolide inhibits transcription factor NF-kappaB and induces apoptosis of multiple myeloma cells. Leuk Res. 2005;29(1):99–105.
   PubMed Web of Science ®Google Scholar
• Long C, Xu Q-B, Ding L, et al. Triptolide inhibits human telomerase reverse transcriptase by downregulating translation factors SP1 and c-Myc in Epstein-Barr virus-positive B lymphocytes. Oncol Lett. 2021;21(4):280.
   PubMed Web of Science ®Google Scholar
• Zhang C, et al. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta Pharmacol Sin. 2006;27(11):1438–1446.
   PubMed Web of Science ®Google Scholar
• Guan J, et al. Triptolide induces DNA breaks, activates caspase-3-dependent apoptosis and sensitizes B-cell lymphoma to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors. Oncol Lett. 2017;14(4):4965–4970.
   PubMed Web of Science ®Google Scholar
• Huang Y, et al. Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial-mesenchymal transition via regulating the PI3K/AKT/mTOR pathway. Onco Targets Ther. 2018;12(11):769–779.
   Google Scholar
• Kang D, Liu Y, Song Y, et al. Triptolide shows high sensitivity and low toxicity against acute myeloid leukemia cell lines through inhibiting WSTF-RNAPII complex. Front Oncol. 2022 Feb 16;12:811850.
   PubMed Web of Science ®Google Scholar
• Zhang D, et al. Raman spectrum reveals the cell cycle arrest of Triptolide-induced leukemic T-lymphocytes apoptosis. Spectrochim Acta A Mol Biomol Spectrosc. 2015;15(141):216–222.
   Google Scholar
• Zhao F, et al. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol. 2010;646(1-3):1–11.
   PubMed Web of Science ®Google Scholar
• Wu X, et al. Triptolide promotes ferroptosis by suppressing Nrf2 to overcome leukemia cell resistance to doxorubicin. Mol Med Rep. 2023;27(1):17.
   PubMed Web of Science ®Google Scholar
• Nam LB, Choi WJ, Keum Y-S. Triptolide downregulates the expression of NRF2 target genes by increasing cytoplasmic localization of NRF2 in A549 cells. Front Pharmacol. 2021 Sep 8;12:680167.
   PubMed Web of Science ®Google Scholar
• Shi P, Zha J, Feng J, et al. Low-dose triptolide enhanced activity of Idarubicin against acute myeloid leukemia stem-like cells via inhibiting DNA damage repair response. Stem Cell Rev Rep. 2021 Apr;17(2):616–627.
   PubMed Web of Science ®Google Scholar
• Chen Q, et al. Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and-independent pathways. Exp Hematol Oncol. 2022;11(1):23.
   PubMed Web of Science ®Google Scholar
• Zhu M, et al. Role of Apg-1 in HSF1 activation and bortezomib sensitivity in myeloma cells. Exp Hematol. 2020;81:50–59.
   PubMed Web of Science ®Google Scholar
• Yang M, et al. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med. 2008;22(4):489–496.
   PubMed Web of Science ®Google Scholar
• Huang X, et al. Triptolide enhances the sensitivity of multiple myeloma cells to dexamethasone via microRNAs. Leuk Lymphoma. 2012;53(6):1188–1195.
   PubMed Web of Science ®Google Scholar
• Hua H-Y, et al. Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM 1 human myelodysplastic syndrome cell line. Mol Med Rep. 2016;14(5):4180–4186.
   PubMed Web of Science ®Google Scholar
• Ebian HF, Abdelnabi AM, Abdelazem AS, et al. Peripheral blood CD26 positive leukemic stem cells as a possible diagnostic and prognostic marker in chronic myeloid leukemia. Leuk Res Rep. 2022 May 9;17:100321.
   PubMedGoogle Scholar
• Maitre E, Cornet E, Salaün V, et al. Immunophenotypic analysis of hairy cell leukemia (HCL) and hairy cell leukemia-like (HCL-like) disorders. Cancers (Basel). 2022 Feb 18;14(4):1050.
   PubMed Web of Science ®Google Scholar
• Sharma P, Sachdeva MUS, Naseem S, et al. Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia. Int J Lab Hematol. 2022 Jun;44(3):518–523.
   PubMed Web of Science ®Google Scholar
• Angevin E, Isambert N, Trillet-Lenoir V, et al. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. Br J Cancer. 2017;116(9):1126–1134.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Madokoro H, Yamada K, et al. novel antibody-drug conjugate with anti-CD26 humanized monoclonal antibody and transcription factor IIH (TFIIH) inhibitor, triptolide, inhibits tumor growth via impairing mRNA synthesis. Cancers (Basel). 2019 Aug 8;11(8):1138.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Madokoro H, Yamada K, et al. A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition. Cancer Cell Int. 2016 Apr 30;16:35.
   PubMed Web of Science ®Google Scholar
• Kang D, et al. Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia. Eur J Med Chem. 2022 Dec 5;243:114694.
   PubMed Web of Science ®Google Scholar